Lipid abnormalities associated with protease inhibitors.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Lipid abnormalities associated with protease inhibitors.

J Assoc Nurses AIDS Care. 1999 Mar-Apr;10(2):22-30. Unique Identifier : AIDSLINE MED/99164801
Melroe NH; Kopaczewski J; Henry K; Huebsch J; HIV Programs at Regions Hospital in St. Paul, Minnesota, USA.

Abstract: Treatment for HIV infection in the past 3 years has significantly improved the prognosis of people infected with HIV. Protease inhibitors have played a critical role in this improved prognosis. Recent findings indicate, however, that protease inhibitors may cause significant alterations in lipid metabolism. This study reviewed the incidence of lipid abnormalities associated with the use of three different protease inhibitor therapies and identified that 56% of those who were assessed had abnormal elevated lipids. Following initiation of the protease inhibitor, a significant increase in cholesterol was found in 80% of the patients on norvir/saquinavir, 51% of patients on indinavir, and 47% of patients on nelfinavir. These lipid alterations have added a new and unexpected health risk for HIV-infected persons. The risks of therapy with protease inhibitors may have a greater life-threatening potential than the disease itself. This article will review the published findings suggestive of protease inhibitor hyperlipidemia and will highlight the findings of these events in a clinical setting. The purpose of this article is to alert the nursing community of this potential serious side effects and to make recommendations that may be put into practice so that complications may be reduced.

Keywords: JOURNAL ARTICLE Adult Drug Monitoring Female Human Hyperlipidemia/BLOOD/*CHEMICALLY INDUCED/COMPLICATIONS HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/*ADVERSE EFFECTS Male Practice Guidelines Retrospective Studies Risk Factors
990730
A9971213

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .